U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
149124
Name Type Language
vanucizumab [INN]
Preferred Name English
VANUCIZUMAB
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
C0U97738AE
Common Name English
IMMUNOGLOBULIN RECOMBINED G1-KAPPA/LAMBDA, ANTI-(HOMO SAPIENS ANGPT2 (ANGIOPOIETIN 2, ANG2))/ANTI-HOMO SAPIENS VEGFA (VASCULAR ENDOTHELIAL GROWTH FACTOR A, VEGF-A, VEGF)), HUMANIZED MONOCLONAL ANTIBODY
Common Name English
BISPECIFIC HUMAN ANTI-ANG-2/ANTI-VEGF-A MONOCLONAL ANTIBODY
Common Name English
RG7221
Code English
RG-7221
Code English
Vanucizumab [WHO-DD]
Common Name English
BISPECIFIC HUMAN ANTI-ANG-2/ANTI-VEGF-A ANTIBODY
Common Name English
RO5520985
Code English
RO-5520985
Code English
VANUCIZUMAB [USAN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1742
Created by admin on Tue Apr 01 16:23:33 GMT 2025 , Edited by admin on Tue Apr 01 16:23:33 GMT 2025
NCI_THESAURUS C129822
Created by admin on Tue Apr 01 16:23:33 GMT 2025 , Edited by admin on Tue Apr 01 16:23:33 GMT 2025
NCI_THESAURUS C1454
Created by admin on Tue Apr 01 16:23:33 GMT 2025 , Edited by admin on Tue Apr 01 16:23:33 GMT 2025
Code System Code Type Description
FDA UNII
B800Z06O8K
Created by admin on Tue Apr 01 16:23:33 GMT 2025 , Edited by admin on Tue Apr 01 16:23:33 GMT 2025
PRIMARY
DRUG BANK
DB12317
Created by admin on Tue Apr 01 16:23:33 GMT 2025 , Edited by admin on Tue Apr 01 16:23:33 GMT 2025
PRIMARY
WIKIPEDIA
Vanucizumab
Created by admin on Tue Apr 01 16:23:33 GMT 2025 , Edited by admin on Tue Apr 01 16:23:33 GMT 2025
PRIMARY
CAS
1448221-05-3
Created by admin on Tue Apr 01 16:23:33 GMT 2025 , Edited by admin on Tue Apr 01 16:23:33 GMT 2025
PRIMARY
NCI_THESAURUS
C118578
Created by admin on Tue Apr 01 16:23:33 GMT 2025 , Edited by admin on Tue Apr 01 16:23:33 GMT 2025
PRIMARY
USAN
CD-98
Created by admin on Tue Apr 01 16:23:33 GMT 2025 , Edited by admin on Tue Apr 01 16:23:33 GMT 2025
PRIMARY
SMS_ID
100000163083
Created by admin on Tue Apr 01 16:23:33 GMT 2025 , Edited by admin on Tue Apr 01 16:23:33 GMT 2025
PRIMARY
INN
9950
Created by admin on Tue Apr 01 16:23:33 GMT 2025 , Edited by admin on Tue Apr 01 16:23:33 GMT 2025
PRIMARY
ChEMBL
CHEMBL3545259
Created by admin on Tue Apr 01 16:23:33 GMT 2025 , Edited by admin on Tue Apr 01 16:23:33 GMT 2025
PRIMARY
EVMPD
SUB177209
Created by admin on Tue Apr 01 16:23:33 GMT 2025 , Edited by admin on Tue Apr 01 16:23:33 GMT 2025
PRIMARY
LEGACY_FDA_UNII
C0U97738AE
Created by admin on Tue Apr 01 16:23:33 GMT 2025 , Edited by admin on Tue Apr 01 16:23:33 GMT 2025
PRIMARY
ACTIVE MOIETY
VANUCIZUMAB
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966